Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04735835
Other study ID # PREDICT 3
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 20, 2020
Est. completion date December 20, 2024

Study information

Verified date July 2023
Source Zoe Global Limited
Contact Meaghan Reardon
Phone 866-771-7478
Email meaghan@joinzoe.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PREDICT 3 study will build on previous research in over 2,000 individuals to further refine machine learning models that predict individual responses to foods, with the aim of advancing precision nutrition science and individualized dietary advice. The study incorporates both standardized and controlled dietary intervention, for the purpose of testing postprandial responses to specific mixed meals, in addition to a free-living period with a dietary record for measuring responses to a large variety of meals consumed in a realistic context, where the role of external factors (e.g. exercise, sleep, time of day) on postprandial responses may be determined. For the first time this PREDICT study is built on top of a commercial product which will allow access to a much larger group of participants who are already collecting large amounts of data through digital and biochemical devices that can contribute to science.


Description:

Choice of design: The study is a single arm mechanistic intervention study. Study population: The subject must have enrolled in the commercial ZOE testing program in order to apply for participation in the PREDICT 3 research program. Screening Assessment: The study eligibility criteria listed below closely match to the commercial eligibility criteria, which ZOE users consent to before enrolling in the commercial program. Study duration: Each participant will take part in the study for 6-14 days. Dietary intervention: The dietary intervention will be carried out on up to 6 days with the option to continue monitoring for a total study period of 14-days. On day one, participants will be asked to fit glucose monitor. Over the following consecutive days, each participant will be instructed to eat 2 standardized meals. Participants are free to eat whatever they wish at all other times. The standardized meals will be provided to all participants by the study team via post. The foods included as part of these meals will be foods that are commonly consumed and can be made from products sold in US supermarkets. Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any left-over food via a digital app for which training will be provided at the start of the study. Following completion of standardized meal period, participants are free to eat and drink whatever they wish and will be asked to track all meals, snacks and drinks on their digital app. Participants will also be advised not to change their physical activity patterns during the course of the study. Regular contact will be made with the participants via phone, their app and text messages for the period of the intervention to encourage compliance and answer any queries. Anthropometry: The participant will be instructed to report height and weight. Dietary and Lifestyle: Participants will be asked to complete a baseline questionnaire online, as well as a diet history questionnaire with portion sizes about the month preceding their study period. They will be asked to record on a daily basis their dietary, activity, and psychological data (e.g. hunger) using a digital mobile phone app. Training in all apps and equipment will be given through written and online instructions and via communications with the study support staff. Digital devices: Participants will be asked to record daily dietary and activity information using digital apps and lifestyle information will be monitored using a wearable device. The continuous glucose monitor (Freestyle Libre, CGM) provides continuous glucose profiles for up to 14 days. The CGM will be inserted on the back of the upper arm, one day before participants begin dietary intervention. This will measure subcutaneous interstitial fluid glucose concentrations every 5 minutes. The CGM will be removed at the end of the intervention period by the participant. A contact number will be made available to participants for any inquiries or if any problems arise. Data from the CGM will be downloaded, and glucose profiles will be evaluated on the basis of data collected. Meal responses: As a product user, the participant will consume standardized meals an additional day to the study intervention. Blood samples: As a product user, the participant will collect postprandial blood on 1 day using finger-prick blood sampling. Stool sample: As a product user, the participant will collect a stool sample on 1 day. Digital app: As product users, participants will be asked to download an app designed specifically for this study, which provides diet logging functionality similar to widely used existing apps such as MyFitnessPal. Participants will be asked to record and monitor the following information via the digital app: - All food and drink they consume, with serving sizes and photos - Sleep and physical activity patterns, including exercise - Hunger and alertness ratings - Psychological feeling of energy and mood - Prescription and over-the-counter drug consumption The app will be available in versions for iOS operating systems. The app will synchronize remotely with backend database servers, over an encrypted and authenticated API, and will support offline operation for when patients wish to record an entry without network coverage. This continuous background synchronization means that it will not be necessary to explicitly download data from the phone at the end of the study. Following the 2020 pandemic of COVID-19, participants are asked to use the COVID-19 Symptom Tracker app to record their physical health symptoms, or lack thereof, attributable to COVID-19, as well as demographic and other health information to track the spread of disease in real time, and to potentially reveal risk factors for infection and severe illness. Subcohort: An opt-in follow-on study will be offered to participants to follow dietary guidance from the ZOE app based on their PREDICT 3 results. During the first 4 weeks, participants will be given dietary guidance to follow from the ZOE app. Thereafter, for a period of up to 12 months, participants will be asked to report on outcome measures at regular intervals (monthly). Outcome measures will be reported before, during and after the 4 week period and include weight, bristol stool chart, bowel habits, hunger, energy, adherence to dietary advice, and app usage. The data will be used to test the efficacy of the ZOE dietary advice in promoting weight loss and improvement of overall health, and may be stratified by age, sex, BMI, adherence and/or motivation to take part in the PREDICT 3 study. Food Frequency Questionnaire Validation: A food-frequency questionnaire (FFQ) developed using the most frequently logged foods within the ZOE app will be validated against a 4-day period of food logging in the app as well as the commonly used US-based DHQ3 FFQ (target enrollment; n=100).


Recruitment information / eligibility

Status Recruiting
Enrollment 250000
Est. completion date December 20, 2024
Est. primary completion date December 20, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Enrolled in the commercial ZOE testing program - Any sex - Minimum 18 years of age (minimum 19 years of age in Alabama and Nebraska due to state laws) - Body mass index (BMI) of greater than or equal to 16.5 kg/m2. - Living in the continental US states, other than in New York (excluded from the ZOE testing product also as they are unable to access the dried blood spot service provided by Quest), or living in the UK - Able and willing to comply with the study protocol and provide informed consent. - Under care for chronic medical conditions (including eating disorders, type 1 diabetes, type 2 diabetes), and confirm they have checked with their primary care physician that this study is safe for them (US cohort only) Exclusion Criteria: - Cannot safely eat the pre-made test meals which contain standard US ingredients, e.g. due to allergy or recent gastrointestinal surgery, or are unwilling to consume these foods. - Are pregnant. - Have had a heart attack (myocardial infarction), stroke/transient ischemic attack (TIA), or major surgery in the last two months. - Are unable to read and write in English, as the ZOE app is only available in English.

Study Design


Intervention

Other:
Dietary Intervention
To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.

Locations

Country Name City State
United Kingdom King's College London London
United States Zoe US Inc. Needham Massachusetts

Sponsors (4)

Lead Sponsor Collaborator
Zoe Global Limited Harvard School of Public Health (HSPH), Massachusetts General Hospital, Stanford University

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Adherence (in sub-cohort) Self-reported in-app question on daily frequency of adherence (categorical) Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)
Other Hunger (in sub-cohort) Self-reported in-app question on hunger levels (categorical) Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
Other Weight (in sub-cohort) Body Weight (kg) Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)
Other Bristol Stool Category (in sub-cohort) Self-reported in-app Bristol Stool chart question (categorical) Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
Other Bowel Frequency (in sub-cohort) Self-reported in-app question on bowel frequency Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
Other Energy (in sub-cohort) Self-reported in-app question on energy levels (categorical) Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
Other Waist Circumference (in sub-cohort) Self-reported in-app question on waist circumference Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)
Other Hip Circumference (in sub-cohort) Self-reported in-app question on hip circumference Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)
Primary Glucose Measurement of blood glucose by continuous glucose monitor (mmol/L) 6-14 days
Primary Gut microbiome species richness Species count in fecal sample (as part of ZOE testing program) 1 day
Primary Blood Lipids Measurement of baseline and 6-h post-prandial triglycerides (mmol/L) by dried blood sample (as part of ZOE testing program) 1 day
Primary Hunger and appetite assessment Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program) 6-14 days
Primary Glucose and HbA1c Measurement of baseline glucose (mmol/L) and HbA1c (%) by dried blood sample (as part of ZOE testing program) 2 days
Secondary Dietary assessment Weighed food log 6-14 days
Secondary Anthropometry Weight (kg) (as part of ZOE testing program) 1 day
Secondary Anthropometry Height (cm) (as part of ZOE testing program) 1 day
Secondary Dietary assessment Diet history and portion size questionnaire about the preceding month (as part of ZOE testing program) 1 month
Secondary Bowel Type and Habit Measurement by Bristol Stool Chart and Questionnaire (as part of ZOE testing program) 6-14 days
Secondary Perceived Energy Assessment Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program) 6-14 days
Secondary Covid-19 symptom assessment Self-reported demographic and physical health symptoms, or lack thereof, reported on a daily basis (as part of ZOE testing program) 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1